LIXTE’s LB-100 Targets Precision Oncology: Enhancing Chemo & Reducing Side Effects

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is making strides in precision oncology with its lead compound LB-100, a novel small-molecule PP2A inhibitor designed to enhance the efficacy of chemotherapy and radiation while reducing side effects. The company focuses on improving the therapeutic index of existing cancer treatments, addressing a key challenge in oncology: maximizing impact while minimizing damage to healthy tissue. LB-100 has demonstrated tolerability and anti-cancer activity in clinical trials, and its mechanism—activation lethality—represents a new field in cancer biology. LIXTE is currently conducting proof-of-concept trials for ovarian clear cell carcinoma and metastatic colon cancer, with a comprehensive patent portfolio protecting its approach.

The news release highlights LIXTE’s collaboration with TinyGems, a specialized communications platform under the Dynamic Brand Portfolio of IBN. TinyGems focuses on innovative small-cap and mid-cap companies, offering services such as press release distribution via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions. The platform aims to cut through information overload, providing clients with brand awareness and recognition. TinyGems is powered by IBN, a comprehensive corporate communications network.

For investors, LIXTE’s progress with LB-100 and its potential to improve cancer treatment outcomes is significant. The company’s approach could reshape how chemotherapy and immunotherapy are combined, offering hope for better patient outcomes. With ongoing clinical trials and a strong patent portfolio, LIXTE is poised to advance precision oncology. The full article is available at https://ibn.fm/EE6ya, and more information on LIXTE can be found at www.lixte.com. TinyGems provides a platform for such emerging companies to reach investors and the public effectively.